<DOC>
	<DOCNO>NCT00857324</DOCNO>
	<brief_summary>The purpose study determine whether association ZMP safe provide benefit patient relapsed/refractory MM .</brief_summary>
	<brief_title>Study Vorinostat Plus Melphalan Prednisone ( Zmp ) Advanced , Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age ≥ 18 year Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance study relate procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal 24 consecutive month surgically sterilize agree continuous abstinence heterosexual sexual contact willing use effective contraception 4 week prior begin study drug therapy , study drug therapy ( include dose interruption ) 4 week discontinuation therapy ; female patient pregnant nursing ; female negative pregnancy test . Male patient agree use acceptable method contraception study drug therapy ( include dose interruption ) 4 week discontinuation Vorinostat therapy . Patient previously diagnose symptomatic MM base standard criterion , measurable disease . Patient relapse refractory minimum 3 week prior therapy ( patient must recover toxicity relate prior therapy ) . Patient Karnofsky performance status ≥ 60 % . Patient lifeexpectancy &gt; 3 month . Any serious medical condition , laboratory abnormality , psychiatric illness social situation would prevent subject signing informed consent form limit compliance study medication requirement . Pregnant beast feeding female . Use concomitant standard/experimental antimyeloma drug therapy . Known positive HIV active infectious hepatitis , type B C. Known congenital long QT syndrome . Ongoing therapy antiarrhythmic drug medicinal product lead QT prolongation cumulative high dose anthracycline . Any clinically significant illness would , investigator 's opinion , increase patient 's risk toxicity . Patients plasmacell leukaemia define presence 20 % plasma cell peripheral blood absolute plasma cell count least 2000/uL . Patients currently active malignancy , except non melanoma skin cancer carcinoma situ cervix . Patients consider currently active second malignancy complete therapy prior malignancy disease free prior malignancy &gt; 5 year consider physician less 30 % risk relapse History allergic reaction relate study drug . Prior exposure HDACi . Patients expose valproic acid could eligible wash period least 30 day . Patients schedule undergo autologous allogenic bone marrow transplant within 4 week initiation Vorinostat administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Refractory relapse patient</keyword>
	<keyword>dose-finding</keyword>
	<keyword>Vorinostat</keyword>
</DOC>